Economic evaluation of pediatric cancer treatment: A systematic literature review

Pediatrics

Volumn 131, Issue 1, 2013, Pages

  Russell, Heidi V ^a,b   Panchal, Janki ^b   VonVille, Helena ^b,c   Franzini, Luisa ^b   Swint, J Michael ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cancer; Child and adolescent; Cost; Economic evaluation; Systematic review

Indexed keywords

ALLOPURINOL; AMIFOSTINE; AMIKACIN; ANTIEMETIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CEFIXIME; CEFTAZIDIME; CLOXACILLIN; GRANULOCYTE COLONY STIMULATING FACTOR; MEROPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; RASBURICASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOPOTECAN;

ADRENALECTOMY; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMIC EVALUATION; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERVENTION STUDY; LEUKEMIA; LYMPHOMA; MEDULLOBLASTOMA; NEUTROPENIA; PRIORITY JOURNAL; PROTON THERAPY; QUALITY CONTROL; REVIEW; SOCIAL STATUS; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

CHILD; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; PEDIATRICS; TREATMENT OUTCOME;

EID: 84872853586     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0912     Document Type: Review

References (63)

1. Smith MA, Seibel NL, Altekruse SF, et al Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol. 2010;28(15):2625-2634
2. Price AS, Stranges E, Elixhauser, A. Pediatric cancer hospitalizations, 2009. Statistical Brief #132. Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. Available at: Www.hcup-us. ahrq.gov/reports/statbriefs/sb132.pdf. Accessed October 29, 2012
3. Bloom BS, Knorr RS, Evans AE. The epidemiology of disease expenses. The costs of caring for children with cancer. JAMA. 1985;253(16):2393-2397
4. Luo W, Lane R, Stobart K, et al. The medical care cost of childhood and adolescent cancer in Manitoba, 1990-1995. Chronic Dis Can. 2002;23(3):83-90
5. Hendrickson KC, Rimar J. Patterns of hospital resource utilization of children with leukemia and CNS tumors: A comparison of children who survive and those who die within 3 years of diagnosis. Nurs Econ. 2009;27(1):35-44
6. Barr R, Furlong W, Horsman J, Feeny D, Torrance G, Weitzman S. The monetary costs of childhood cancer to the families of patients. Int J Oncol. 1996;8(5):933-940
7. Tsimicalis A, Stevens B, Ungar WJ, McKeever P, Greenberg M. The cost of childhood cancer from the family's perspective: A critical review. Pediatr Blood Cancer. 2011;56(5): 707-717
8. Goeree R, He J, O'Reilly D, et al. Transferability of health technology assessments and economic evaluations: A systematic review of approaches for assessment and application. Clinicoecon Outcomes Res. 2011;3:89-104
9. Parsons SK, Cohen JT, Lichte ML. Economic issues in pediatric cancer. In: Philip Pizzo DP, ed. Principals and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2010:1428-1440
10. Kirchhoff AC, Krull KR, Ness KK, et al. Physical, mental, and neurocognitive status and employment outcomes in the childhood cancer survivor study cohort. Cancer Epidemiol Biomarkers Prev. 2011;20(9): 1838-1849
11. US Department of Labor. Consumer price index. 2012. Available at: Http://data.bls. gov/cgi-bin/cpicalc.pl. Accessed October 29, 2012
12. Oanda. Oanda currency converter. 2012. Available at: Http://www.oanda. com/currency/converter/. Accessed October 29, 2012
13. Drummond MFSM, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Healthcare Programs, 3rd ed. New York, NY: Oxford University Press; 2005
14. Gonzalez-Perez JG. Developing a scoring system to quality assess economic evaluations. Eur J Health Econ. 2002;3(2):131-136
15. Teuffel O, Amir E, Alibhai SM, Beyene J, Sung L. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics. 2011;127(2). Available at: Www.pediatrics.org/cgi/content/full/127/ 2/e279-
16. Agaoglu L, Devecioglu O, Anak S, et al. Costeffectiveness of cefepime 1 netilmicin or ceftazidime 1 amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother. 2001;13(3):281-287
17. Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: An update. Clin Microbiol Infect. 2006;12(7):606-620
18. Klaassen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J Pediatr Hematol Oncol. 2000;22(5):405-411
19. Santolaya ME, Alvarez AM, Avilés CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol. 2004;22(18):3784-3789
20. Corapçioglu F, Sarialioglu F, Olgun N, Uysal KM. Analysis of 136 febrile neutropenic episodes in children with cancer: Evaluation of treatment effectiveness and cost. Pediatr Hematol Oncol. 2004;21(6):535-543
21. Corapçioglu F, Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: A prospective randomized trial of the treatment efficacy and cost. Pediatr Hematol Oncol. 2005;22(1):59-70
22. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/ tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: A randomized comparison. Pediatr Hematol Oncol. 2006;23(3):177-186
23. Ammann RA, Leibundgut K, Hirt A, Ridolfi Lüthy A. Individual timing of blood counts in G-CSF prophylaxis after myelosuppressive chemotherapy reduces G-CSF injections, blood counts, and costs: A prospective randomized study in children and adolescents. Support Care Cancer. 2002;10(8): 613-618
24. Bennett CL, Stinson TJ, Lane D, Amylon M, Land VJ, Laver JH. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: A case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol. 2000;34(2):92-96
25. Little MA, Morland B, Chisholm J, et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol. 2002;38(2):98-103
26. Delorme J, Badin S, Le Corroller AG, et al. Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003;25(6):441-447
27. González-Vicent M, Madero L, Sevilla J, Díaz MA. Clinical and economic evaluation of using granulocyte colony-stimulating factor after autologous peripheral blood progenitor cell transplantation in children. Haematologica. 2002;87(1):105-106
28. González-Vicent M, Madero L, Sevilla J, Ramirez M, Díaz MA. A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplant. 2004;34(12): 1077-1081
29. Valteau-Couanet D, Faucher C, Aupérin A, et al. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: Results of a SFGM-TC randomised trial. Bone Marrow Transplant. 2005; 36(6):547-552
30. Yeoh EJ, Cunningham JM, Yee GC, et al. Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells. Bone Marrow Transplant. 2001;28(6):563-571
31. Madero L, González Vincent M, Ramirez M, Quintero V, Benito A, Díaz MA. Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplant. 2000;26(3):269-273
32. Vicent MG, Madero L, Chamorro L, Madero R, Diaz MA. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. Haematologica. 2001;86(10):1087-1094
33. Lin YF, Lairson DR, Chan W, et al. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010;16(9):1272-1281
34. Majhail NS, Mothukuri JM, Macmillan ML, et al. Costs of pediatric allogeneic hematopoieticcell transplantation. Pediatr Blood Cancer. 2010;54(1):138-143
35. Lundkvist J, Ekman M, Ericsson SR, Jönsson B, Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer. 2005;103(4):793-801
36. van den Akker-van Marle ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: A case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics. 2006;7(5):783-792
37. Dionne F, Mitton C, Rassekh R, et al. Economic impact of a genetic test for cisplatininduced ototoxicity. Pharmacogenomics J. 2012;12(3):205-213
38. Stevens B, Croxford R, McKeever P, et al. Hospital and home chemotherapy for children with leukemia: A randomized crossover study. Pediatr Blood Cancer. 2006;47 (3):285-292
39. Kurre HA, Ettinger AG, Veenstra DL, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli Lasparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: The Children's Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 2002;24 (3):175-181
40. Hancock-Howard R, Connolly BL, McMahon M, et al. Cost-effectiveness analysis of implantable venous access device insertion using interventional radiologic versus conventional operating room methods in pediatric patients with cancer. J Vasc Interv Radiol. 2010;21(5):677-684
41. Barr RD, Feeny D, Furlong W. Economic evaluation of treatments for cancer in childhood. Eur J Cancer. 2004;40(9):1335-1345
42. Charnas R, Lüthi AR, Ruch W; Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J. 1997;16(4):346-353
43. Pickard AS, Topfer LA, Feeny DH. A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia. J Natl Cancer Inst Monogr. 2004;(33):102-125
44. Tchouaket EN, Lamarche PA, Goulet L, Contandriopoulos AP. Health care system performance of 27 OECD countries. Int J Health Plann Manage. 2012;27(2):104-129
45. Jain R, Grabner M, Onukwugha E. Sensitivity analysis in cost-effectiveness studies: From guidelines to practice. Pharmacoeconomics. 2011;29(4):297-314
46. Backhouse ME. Use of randomised controlled trials for producing cost-effectiveness evidence: Potential impact of design choices on sample size and study duration. Pharmacoeconomics. 2002;20(15):1061-1077
47. Gardiner JC, Huebner M, Jetton J, Bradley CJ. Power and sample assessments for tests of hypotheses on cost-effectiveness ratios. Health Econ. 2000;9(3):227-234
48. Brower WB, van Exel MJ, Tilford JM. Incorporating cargiver and family effects in economic evaluations of child health. In: Ungar WJ, ed. Economic Evaluation in Child Health. Oxford, United Kingdom: Oxford University Press; 2010:55-76
49. Tarride JE, Burke N, Bischof M, et al. A review of health utilities across conditions common in paediatric and adult populations. Health Qual Life Outcomes. 2010;8: 12
50. van Litsenburg RR, Uyl-de Groot CA, Raat H, Kaspers GJ, Gemke RJ. Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: The influence of new medication and diagnostic technology. Pediatr Blood Cancer. 2011;57 (6):1005-1010
51. Hall WA, Kowalik K, Liu H, Truwit CL, Kucharezyk J. Costs and benefits of intraoperative MR-guided brain tumor resection. Acta Neurochir Suppl (Wien). 2003; 85:137-142
52. Stanford A, Upperman JS, Nguyen N, Barksdale E Jr, Wiener ES. Surgical management of open versus laparoscopic adrenalectomy: Outcome analysis. J Pediatr Surg. 2002;37(7):1027-1029
53. Ferrara F, Ravasio R. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with goodprognosis diffuse large-B-cell lymphoma. Clin Drug Investig. 2008;28(1):55-65
54. Donnan JR, Ungar WJ, Mathews M, Hancock-Howard RL, Rahman P. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(2):231-239
55. Miano M, Manfredini L, Garaventa A, et al. Feasibility of a home care program in a pediatric hematology and oncology department. Results of the first year of activity at a single Institution. Haematologica. 2002;87(6):637-642
56. Mahadeo KM, Santizo R, Baker L, Curry JO, Gorlick R, Levy AS. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. Pediatr Blood Cancer. 2010; 55(7):1296-1299
57. Annemans L, Moeremans K, Lamotte M, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer. 2003;11(4):249-257
58. Eaddy M, Seal B, Tangirala M, Davies EH, O'Day K. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. Am J Health Syst Pharm. 2010;67(24):2110-2114
59. Walker PC, Biglin KE, Constance TD, Bhambhani K, Sims-McCallum R. Promoting the use of oral ondansetron in children receiving cancer chemotherapy. Am J Health Syst Pharm. 2001;58(7):598-602
60. Corapçioglu F, Sarper N. A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer. Pediatr Hematol Oncol. 2005;22(2):103-114
61. Iannalfi A, Bernini G, Caprilli S, Lippi A, Tucci F, Messeri A. Painful procedures in children with cancer: Comparison of moderate sedation and general anesthesia for lumbar puncture and bone marrow aspiration. Pediatr Blood Cancer. 2005;45(7): 933-938
62. Stolarska M, Mlynarski W, Zalewska-Szewczyk B, Bodalski J. Cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases-a clinical study including the pharmacoeconomic analysis. Pharmacol Rep. 2006;58(1):30-34
63. Abbott LS, Deevska M, Fernandez CV, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood. 2009;114(25):5146-5151